Parr Mcknight Wealth Management Group LLC Has $1.07 Million Position in Zoetis Inc. $ZTS

Parr Mcknight Wealth Management Group LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 54.2% in the fourth quarter, HoldingsChannel reports. The fund owned 8,509 shares of the company’s stock after selling 10,051 shares during the period. Parr Mcknight Wealth Management Group LLC’s holdings in Zoetis were worth $1,071,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ZTS. Verity & Verity LLC lifted its position in shares of Zoetis by 3.1% in the fourth quarter. Verity & Verity LLC now owns 3,612 shares of the company’s stock valued at $454,000 after buying an additional 108 shares during the last quarter. MUFG Securities EMEA plc raised its holdings in Zoetis by 113.0% in the 4th quarter. MUFG Securities EMEA plc now owns 18,066 shares of the company’s stock valued at $2,273,000 after acquiring an additional 9,583 shares in the last quarter. Sfmg LLC raised its position in Zoetis by 4.6% during the fourth quarter. Sfmg LLC now owns 22,900 shares of the company’s stock valued at $2,881,000 after purchasing an additional 1,017 shares in the last quarter. Forsta AP Fonden raised its stake in Zoetis by 7.1% during the fourth quarter. Forsta AP Fonden now owns 213,400 shares of the company’s stock worth $26,850,000 after acquiring an additional 14,200 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Zoetis during the fourth quarter worth $734,425,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
• Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
• Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
• Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

Zoetis Stock Up 0.2%

Zoetis stock opened at $77.81 on Monday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The firm’s 50-day simple moving average is $104.29 and its 200 day simple moving average is $117.01. The stock has a market cap of $32.62 billion, a PE ratio of 12.90, a price-to-earnings-growth ratio of 1.27 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Research analysts predict that Zoetis Inc. will post 6.89 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Insider Transactions at Zoetis

In other Zoetis news, Director Michael B. Mccallister bought 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were purchased at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent research reports. UBS Group decreased their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. JPMorgan Chase & Co. reduced their target price on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Argus reissued a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $133.92.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.